MTOR and cancer: An array of cancers harboring oncogenic alterations of PIK3CA, KRAS, PTEN, EGFR, and RHOA have been reported to be associated with activated PI3K/AKT-mTOR signaling (Gouw et al, 2017; Kumagai et al, 2020; Sugiyama et al, 2020a; Sun et al, 2021; Tewari et al, 2022).